Cargando…

The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis

BACKGROUND: Choosing Wisely is a high-profile campaign seeking to reduce the use of low-value care. We investigated the impact of a Choosing Wisely Canada recommendation against using a combination of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the man...

Descripción completa

Detalles Bibliográficos
Autores principales: Laba, Tracey-Lea, Worthington, Heather C., Cheng, Lucy, Chan, Fiona K.I., Bansback, Nick, Law, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Impact Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828945/
https://www.ncbi.nlm.nih.gov/pubmed/36735223
http://dx.doi.org/10.9778/cmajo.20210185
_version_ 1784867373769031680
author Laba, Tracey-Lea
Worthington, Heather C.
Cheng, Lucy
Chan, Fiona K.I.
Bansback, Nick
Law, Michael R.
author_facet Laba, Tracey-Lea
Worthington, Heather C.
Cheng, Lucy
Chan, Fiona K.I.
Bansback, Nick
Law, Michael R.
author_sort Laba, Tracey-Lea
collection PubMed
description BACKGROUND: Choosing Wisely is a high-profile campaign seeking to reduce the use of low-value care. We investigated the impact of a Choosing Wisely Canada recommendation against using a combination of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the management of hypertension, heart failure or diabetic nephropathy on population-level use of these medications in British Columbia, Canada. METHODS: We identified all people (any age) who were continuously registered with BC’s Medical Service Plan between 2010 and 2017 with the targeted conditions. Using prescription claims data and an interrupted time-series analysis, we estimated the number of people on combination therapy per month, the proportion of days covered (PDC) by combination therapy per month and proportion of all combination prescriptions started per month in the 2 years before and after the introduction of the recommendation on Oct. 29, 2014. RESULTS: Of 1 104 593 people (mean age 65 yr, standard deviation 16 yr) in our study cohort, 4.6% were exposed to combination therapy, largely prescribed by family physicians (84%). The number of people on combination therapy and the PDC were declining before the recommendation, but the proportion of combination prescriptions started in the 2 years before the recommendation was increasing. After the recommendation, we observed no statistically significant changes in any outcome. The pre-existing downward trend of the monthly number of people decelerated (16.8, 95% confidence interval [CI] 14.0 to 19.5) and the proportion of prescriptions started increased (0.13%, 95% CI 0.08% to 0.18%). INTERPRETATION: The Choosing Wisely Canada recommendation against using a combination of ACE inhibitors and ARBs was not associated with reduced combination therapy use in the targeted conditions. The observed pre-existing declines in this practice questions the process of selecting recommendations, and the optimal implementation and value of Choosing Wisely campaigns without other reinforcing interventions.
format Online
Article
Text
id pubmed-9828945
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher CMA Impact Inc.
record_format MEDLINE/PubMed
spelling pubmed-98289452023-01-13 The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis Laba, Tracey-Lea Worthington, Heather C. Cheng, Lucy Chan, Fiona K.I. Bansback, Nick Law, Michael R. CMAJ Open Research BACKGROUND: Choosing Wisely is a high-profile campaign seeking to reduce the use of low-value care. We investigated the impact of a Choosing Wisely Canada recommendation against using a combination of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the management of hypertension, heart failure or diabetic nephropathy on population-level use of these medications in British Columbia, Canada. METHODS: We identified all people (any age) who were continuously registered with BC’s Medical Service Plan between 2010 and 2017 with the targeted conditions. Using prescription claims data and an interrupted time-series analysis, we estimated the number of people on combination therapy per month, the proportion of days covered (PDC) by combination therapy per month and proportion of all combination prescriptions started per month in the 2 years before and after the introduction of the recommendation on Oct. 29, 2014. RESULTS: Of 1 104 593 people (mean age 65 yr, standard deviation 16 yr) in our study cohort, 4.6% were exposed to combination therapy, largely prescribed by family physicians (84%). The number of people on combination therapy and the PDC were declining before the recommendation, but the proportion of combination prescriptions started in the 2 years before the recommendation was increasing. After the recommendation, we observed no statistically significant changes in any outcome. The pre-existing downward trend of the monthly number of people decelerated (16.8, 95% confidence interval [CI] 14.0 to 19.5) and the proportion of prescriptions started increased (0.13%, 95% CI 0.08% to 0.18%). INTERPRETATION: The Choosing Wisely Canada recommendation against using a combination of ACE inhibitors and ARBs was not associated with reduced combination therapy use in the targeted conditions. The observed pre-existing declines in this practice questions the process of selecting recommendations, and the optimal implementation and value of Choosing Wisely campaigns without other reinforcing interventions. CMA Impact Inc. 2022-12-13 /pmc/articles/PMC9828945/ /pubmed/36735223 http://dx.doi.org/10.9778/cmajo.20210185 Text en © 2022 CMA Impact Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use) and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Research
Laba, Tracey-Lea
Worthington, Heather C.
Cheng, Lucy
Chan, Fiona K.I.
Bansback, Nick
Law, Michael R.
The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
title The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
title_full The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
title_fullStr The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
title_full_unstemmed The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
title_short The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
title_sort impact of the choosing wisely canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828945/
https://www.ncbi.nlm.nih.gov/pubmed/36735223
http://dx.doi.org/10.9778/cmajo.20210185
work_keys_str_mv AT labatraceylea theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT worthingtonheatherc theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT chenglucy theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT chanfionaki theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT bansbacknick theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT lawmichaelr theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT labatraceylea impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT worthingtonheatherc impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT chenglucy impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT chanfionaki impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT bansbacknick impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis
AT lawmichaelr impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis